← Back to Search

[89Zr]Panitumumab Imaging for Head and Neck Cancer

Phase < 1

Recruiting

Led By Suzanne Lapi, PhD

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Planned standard of care surgery with curative intent for squamous cell carcinoma

Age > 18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5-9 days prior to surgery

Awards & highlights

Study Summary

This trial will compare two ways of looking at tumors to see which is more accurate. It is for people with head and neck cancer who are about to have surgery.

Who is the study for?

This trial is for adults over 18 with newly diagnosed head and neck squamous cell carcinoma, scheduled for surgery. Participants must have normal organ function tests, no history of severe heart or liver conditions within the past 6 months, not be pregnant or breastfeeding, and cannot exceed a weight limit due to scanner size.Check my eligibility

What is being tested?

[89Zr]Panitumumab PET/MRI imaging is being tested against standard [18F-FDG] PET/MRI to see if it's better at finding the exact size and location of tumors in patients with head and neck cancer. This study will not affect treatment plans as it's only for imaging purposes.See study design

What are the potential side effects?

Since this trial focuses on imaging rather than treatment, side effects are minimal but may include allergic reactions to panitumumab tracer components or issues related to MRI procedures like discomfort from lying still.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am scheduled for surgery to remove my squamous cell carcinoma.

Select...

I am older than 18 years.

Select...

I am scheduled for surgery for my newly diagnosed head or neck cancer.

Select...

My cancer has not spread to my lymph nodes according to tests.

Select...

My blood, kidney, and liver tests are within normal ranges.

Select...

I have been diagnosed with squamous cell carcinoma in the head or neck.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5-9 days prior to surgery

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5-9 days prior to surgery

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5-9 days prior to surgery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Image Quality

Trial Design

1Treatment groups

Experimental Treatment

Group I: [89Zr]panitumumab-PET/MRI patientsExperimental Treatment1 Intervention

All study patients will receive [89Zr]Panitumumab-PET/MRI imaging.

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor

1,587 Previous Clinical Trials

2,280,258 Total Patients Enrolled

Suzanne Lapi, PhDPrincipal InvestigatorUniversity of Alabama at Birmingham

1 Previous Clinical Trials

Media Library

[89Zr]Panitumumab Tracer Clinical Trial Eligibility Overview. Trial Name: NCT05183048 — Phase < 1

Head and Neck Squamous Cell Carcinoma Research Study Groups: [89Zr]panitumumab-PET/MRI patients

Head and Neck Squamous Cell Carcinoma Clinical Trial 2023: [89Zr]Panitumumab Tracer Highlights & Side Effects. Trial Name: NCT05183048 — Phase < 1

[89Zr]Panitumumab Tracer 2023 Treatment Timeline for Medical Study. Trial Name: NCT05183048 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical research offer a chance for participation to potential participants?

"The clinical trial listing on clinicaltrials.gov reveals that this particular study is no longer accepting applicants, with the last update occuring in October of 2022. However, 2678 other trials are currently open to enrollment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

Suzanne E. Lapi, PhD 2024. "Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05183048.

All > Squamous Cell Carcinoma